AVDL - Avadel Pharmaceuticals filed for 500M mixed shelf offering

• Avadel Pharmacueticals ( NASDAQ: AVDL ) has filed for a $500M mixed shelf offering .
• The filing does not necessarily indicate that a sale has begun, or will occur in the future.
• The company intends to use the proceeds for general corporate purposes.
• The offering can include ordinary shares, ordinary shares represented by American Depository Shares, preferred shares, debt securities, warrants, and units.
• Avadel has been embroiled in a patent dispute with Jazz Pharma ( JAZZ ) related to the latter’s narcolepsy therapy Xyrem.

For further details see: